HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Evaluation of adjuvant immunochemotherapy in advanced gastric cancer].

Abstract
Evaluation of adjuvant immunochemotherapy using Polysaccharide K (PSK) for advanced gastric cancers was performed by meta-analysis of 6 clinical trials in which 5-year survival has been reported in distinguished journals of Japan. The odds ratio of 0.75 (95% confidence interval 0.62-0.93, p < 0.01) favored immunochemotherapy compared to chemotherapy. In the Chubu district, 3 consecutive trials using PSK were performed beginning in 1977. From meta-analysis of the 2 preceding trials, immunochemotherapy was suggested to be effective in a subgroup of T2 and T3 primary tumor, and PPD skin test positive cases. The third trial was performed in this group of patients and a statistically significant difference (p = 0.044) was observed from the 5-year results.
AuthorsJ Sakamoto, H Nakazato
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 20 Issue 16 Pg. 2525-30 (Dec 1993) ISSN: 0385-0684 [Print] Japan
PMID8279851 (Publication Type: Journal Article, Review)
Chemical References
  • Proteoglycans
  • polysaccharide-K
Topics
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy
  • Meta-Analysis as Topic
  • Proteoglycans (therapeutic use)
  • Stomach Neoplasms (mortality, therapy)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: